Cadrenal Therapeutics' Upcoming Conference Participation
PONTE VEDRA, Fla. — Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a pioneering biopharmaceutical company, is gearing up to share its groundbreaking work in anticoagulation therapy at the Lytham Partners Fall 2025 Investor Conference. This virtual event will occur on September 30, 2025, and will feature a webcast presentation by company representatives, focusing on their latest advancements in therapeutics.
Webcast Presentation Details
When to Listen In
Mark your calendars! The webcast presentation is scheduled for 3:30 p.m. ET. Attendees will be able to access the presentation through the conference homepage, showcasing Cadrenal's commitment to transparency and engagement with investors and healthcare professionals alike.
Replays Available After the Event
The content will be available for replay, allowing stakeholders who cannot attend the live event to stay informed about the company's developments and insights.
One-on-One Investor Meetings
Connect with Management
During the conference, Cadrenal's management team will hold virtual one-on-one meetings to discuss their innovative programs and answer questions from interested investors. To schedule a meeting, participants can reach out to the organizers at Lytham Partners.
Invitation to Discuss Innovations
This is a prime opportunity for investors to engage directly with management and explore the potential of Cadrenal's product pipeline, like tecarfarin, which aims to reshape anticoagulation therapy.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is dedicated to developing transformative therapies that address critical gaps in anticoagulation. The company’s lead investigational product, tecarfarin, represents a novel approach in the realm of anticoagulants, designed to provide safer and more effective options for patients who require chronic anticoagulation.
Innovative Solutions for Anticoagulation Therapy
Tecarfarin is an oral Vitamin K antagonist that targets the prevention of serious cardiovascular events, such as heart attacks and strokes, particularly among patients with challenging treatment needs. Unlike traditional options like warfarin, which are often complicated to manage, tecarfarin aims to simplify therapeutic management and mitigate the serious side effects associated with current anticoagulants.
Achievements and Designations
Tecarfarin has received Orphan Drug Designation (ODD) and fast-track designations for critical applications, particularly in patients with end-stage kidney disease and atrial fibrillation. These designations highlight the urgency and the unmet needs in the anticoagulation space that Cadrenal is poised to address.
Stay Updated and Informed
For More Information
Investors and interested parties are encouraged to visit the official website of Cadrenal Therapeutics for the latest updates and information about their ongoing research and development efforts. By visiting Cadrenal's website, stakeholders can access comprehensive resources and stay abreast of company news.
Contact Information for Inquiries
For media inquiries, please contact Matthew Szot, CFO of Cadrenal Therapeutics, at press@cadrenal.com. Investors looking for detailed discussions can reach out to Robert Blum at Lytham Partners via email at CVKD@lythampartners.com or call 602-889-9700.
Frequently Asked Questions
What is the main focus of Cadrenal Therapeutics?
Cadrenal Therapeutics specializes in developing innovative therapies to improve anticoagulation management, addressing unmet patient needs.
When is the investor conference taking place?
The Lytham Partners Fall 2025 Investor Conference is scheduled for September 30, 2025.
How can investors participate in the presentations?
Investors can attend the webcast presentation by accessing the conference homepage on the scheduled date.
What is tecarfarin?
Tecarfarin is a novel oral anticoagulant being developed by Cadrenal, designed to provide a safer alternative to existing therapies.
How can stakeholders reach Cadrenal for more information?
Stakeholders can visit the Cadrenal Therapeutics website or contact the company directly via email for inquiries and detailed discussions.
